Article
Medicine, General & Internal
Masahiro Tsuboi, Roy S. Herbst, Thomas John, Terufumi Kato, Margarita Majem, Christian Grohe, Jie Wang, Jonathan W. Goldman, Shun Lu, Wu-Chou Su, Filippo de Marinis, Frances A. Shepherd, Ki Hyeong Lee, Nhieu Thi Le, Arunee Dechaphunkul, Dariusz Kowalski, Lynne Poole, Ana Bolanos, Yuri Rukazenkov, Yi-Long Wu
Summary: Among patients with resected, EGFR-mutated, stage IB to IIIA NSCLC, adjuvant osimertinib therapy resulted in significantly longer overall survival compared to placebo in the ADAURA trial. These findings demonstrate that adjuvant osimertinib provides a survival benefit for patients with completely resected, EGFR-mutated, stage IB to IIIA NSCLC.
NEW ENGLAND JOURNAL OF MEDICINE
(2023)
Article
Medicine, General & Internal
D. Planchard, P. A. Janne, Y. Cheng, J. C. -H. Yang, N. Yanagitani, S-W Kim, S. Sugawara, Y. Yu, Y. Fan, S. L. Geater, K. Laktionov, C. K. Lee, N. Valdiviezo, S. Ahmed, J-M Maurel, I Andrasina, J. Goldman, D. Ghiorghiu, Y. Rukazenkov, A. Todd, K. Kobayashi
Summary: The study indicates that first-line treatment with osimertinib-chemotherapy significantly prolongs progression-free survival compared to osimertinib monotherapy in patients with EGFR-mutated advanced NSCLC.
NEW ENGLAND JOURNAL OF MEDICINE
(2023)
Editorial Material
Oncology
Xiuning Le, Monique B. Nilsson, Jacqulyne P. Robichaux, John V. Heymach
Summary: The ARTEMIS study showed that combining the VEGF inhibitor bevacizumab with the EGFR inhibitor erlotinib can significantly improve progression-free survival in patients with EGFR mutant non-small-cell lung cancer, especially in those with brain metastases and the EGFR L858R mutation. This suggests the potential benefits of tailored use of VEGF/EGFR combinations in this patient population.
Article
Oncology
Nicola Colclough, Kan Chen, Peter Johnstrom, Nicole Strittmatter, Yumei Yan, Gail L. Wrigley, Magnus Schou, Richard Goodwin, Katarina Varnas, Sally J. Adua, Minghui Zhao, Don X. Nguyen, Gareth Maglennon, Peter Barton, James Atkinson, Lin Zhang, Annika Janefeldt, Joanne Wilson, Aaron Smith, Akihiro Takano, Ryosuke Arakawa, Mikhail Kondrashov, Jonas Malmquist, Evgeny Revunov, Ana Vazquez-Romero, Mohammad Mahdi Moein, Albert D. Windhorst, Natasha A. Karp, M. Raymond Finlay, Richard A. Ward, James W. T. Yates, Paul D. Smith, Lars Farde, Zack Cheng, Darren A. E. Cross
Summary: The study investigates the potential of osimertinib in treating EGFR-mutant brain metastases, demonstrating its significant brain penetrance and impact on brain tumor growth rate.
CLINICAL CANCER RESEARCH
(2021)
Article
Multidisciplinary Sciences
Yen-Hsiang Huang, Jeng-Sen Tseng, Kuo-Hsuan Hsu, Kun-Chieh Chen, Kang-Yi Su, Sung-Liang Yu, Jeremy J. W. Chen, Tsung-Ying Yang, Gee-Chen Chang
Summary: The study demonstrated that sequential osimertinib treatment following first-generation or second-generation EGFR-TKIs provided good clinical efficacy for EGFR-mutant NSCLC patients with acquired T790M mutation, prolonging progression-free survival and overall survival.
SCIENTIFIC REPORTS
(2021)
Article
Pharmacology & Pharmacy
Qingli Cui, Yanhui Hu, Qingan Cui, Daoyuan Wu, Yuefeng Mao, Dongyang Ma, Huaimin Liu
Summary: Treatment options for osimertinib resistance are limited. Osimertinib combined with bevacizumab (osi + bev) showed superior efficacy compared to chemotherapy combined with bevacizumab (che + bev) for patients with acquired resistance to osimertinib, with improved progression-free survival (PFS) and overall survival (OS).
FRONTIERS IN PHARMACOLOGY
(2022)
Article
Biochemistry & Molecular Biology
Chia-Hung Chen, Bo-Wei Wang, Yu-Chun Hsiao, Chun-Yi Wu, Fang-Ju Cheng, Te-Chun Hsia, Chih-Yi Chen, Yihua Wang, Zhang Weihua, Ruey-Hwang Chou, Chih-Hsin Tang, Yun-Ju Chen, Ya-Ling Wei, Jennifer L. Hsu, Chih-Yen Tu, Mien-Chie Hung, Wei-Chien Huang
Summary: Upregulation of active sodium/glucose co-transporter 1 (SGLT1) was found to confer the development of acquired EGFR TKI resistance and was correlated with poorer clinical outcomes in NSCLC patients. Blockade of SGLT1 overcame this resistance by reducing glucose uptake in NSCLC cells, suggesting a potential strategy to improve the therapeutic efficacy of EGFR TKIs in NSCLC patients.
Article
Pharmacology & Pharmacy
Yue Zeng, Yuanqing Feng, Guihua Fu, Junlan Jiang, Xiaohan Liu, Yue Pan, Chunhong Hu, Xianling Liu, Fang Wu
Summary: The acquired resistance of EGFR-TKIs is inevitable and heterogeneous. Osimertinib is the standard second-line therapy for T790M-positive patients, but its efficacy in patients with concurrent multiple driver gene resistance is unclear. The T790M accompanying other driver gene resistance will be a new subtype, requiring new treatment options.
FRONTIERS IN PHARMACOLOGY
(2022)
Article
Cell Biology
Alessandro Leonetti, Mjriam Capula, Roberta Minari, Giulia Mazzaschi, Alessandro Gregori, Btissame El Hassouni, Filippo Papini, Paola Bordi, Michela Verze, Amir Avan, Marcello Tiseo, Elisa Giovannetti
Summary: Our study found that patients with an increase in miR-21 levels after two months of EGFR-TKI treatment were more likely to experience disease stability/progression. Patients who experienced clinical benefit lasting at least six months showed higher levels of circulating miR-21.
Article
Medicine, General & Internal
Mei-Mei Zheng, Yang-Si Li, Hai-Yan Tu, Hao Sun, Kai Yin, Ben-Yuan Jiang, Jin-Ji Yang, Xu-Chao Zhang, Qing Zhou, Chong-Rui Xu, Zhen Wang, Hua-Jun Chen, De-Xiang Zhou, Yi-Long Wu
Summary: This study revealed site-specific resistant mechanisms to osimertinib and investigated subsequent treatments for leptomeningeal metastases (LM) in EGFR-mutated NSCLC patients. Private resistant mechanisms in cerebrospinal fluid (CSF) might match osimertinib-resistant LM for targeted therapy. Continuing osimertinib with intensification strategy might prolong survival, especially for those with CNS-only progression.
Article
Medicine, General & Internal
Hongxue Meng, Lan Huang, Jiahui Wang, Yingxu Zhou, Meng Wang, Zhaoyang Yang, Xuan Hong
Summary: A retrospective analysis of 67 patients with EGFR mutations who were switched to osimertinib after receiving first-generation EGFR-TKIs revealed that female patients and those who experienced isolated progression during first-line treatment may exhibit a better response to osimertinib. Additionally, a low frequency of the EGFR T790M allele in plasma samples may predict poor efficacy of osimertinib and shorter progression-free survival (PFS).
INTERNATIONAL JOURNAL OF CLINICAL PRACTICE
(2021)
Article
Biochemistry & Molecular Biology
Zhenzhen Pan, Kai Wang, Xiniao Wang, Zhirong Jia, Yuqi Yang, Yalei Duan, Lianzhan Huang, Zhuo-Xun Wu, Jian-ye Zhang, Xuansheng Ding
Summary: This study reveals a common molecular mechanism underlying EGFR-TKIs resistance in non-small cell lung cancer, involving cholesterol accumulation, EGFR/Src/Erk/SP1 axis-mediated ERR alpha re-expression and subsequent cell proliferation. Lowering cholesterol levels and downregulating ERR alpha can overcome resistance to gefitinib and osimertinib.
Review
Oncology
Misako Nagasaka, Viola W. Zhu, Sun Min Lim, Michael Greco, Fengying Wu, Sai-Hong Ignatius Ou
Summary: This review provides an overview of the latest developments in clinical development of third-generation EGFR TKIs, including interim results from some drugs and designs of phase 3 trials, as well as listing other third-generation EGFR TKIs in pipeline development. Additionally, it summarizes the clinical trial results of previously reported third-generation EGFR TKIs and combination clinical trial designs.
JOURNAL OF THORACIC ONCOLOGY
(2021)
Review
Oncology
Daoan Cheng, Banglu Wang, Lige Wu, Rui Chen, Weiqing Zhao, Cheng Fang, Mei Ji
Summary: Lung cancer is the primary cause of cancer-related deaths worldwide. The use of EGFR tyrosine kinase inhibitors has improved survival rates for patients with EGFR-mutated non-small cell lung cancer. However, resistance to these inhibitors, like other anticancer drugs, inevitably develops over time. Exosomes, extracellular vesicles carrying non-coding RNAs, have been found to play a role in the development of EGFR-TKIs resistance. This review provides an overview of the current research on exosomal non-coding RNAs mediating EGFR-TKIs resistance in EGFR-mutated NSCLC, and suggests potential applications in monitoring therapy and developing new treatment strategies.
Article
Oncology
Xiao Liang, Wei Zhang, Jun Li, Jing Zhu, Jun Shao, Jing Wang, Hongshuai Wu, Jiali Dai, Jiali Xu, Wei Wang, Renhua Guo
Summary: This study found that concurrent detection of EGFR mutation in tumor tissue and plasma is an independent prognostic factor for first-line EGFR-TKIs treatment in EGFR-mutated non-small cell lung cancer (NSCLC) patients. Combination therapy may be a promising approach to improve the outcome for these patients.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
(2023)